Vaxcyte, Inc. (PCVX) income statement
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$59.40−2.21 (-3.59%)
Close on Nov 17, 2026Market cap $8.84BP/E –Yield 0.00%
Vaxcyte, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -25.6%
Financial strength
- Current ratio
- 5.72
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 67.5%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.20
- Dividend yield
- 0.00%
See a number that looks wrong?